Elucid
Elucid is a Boston-based AI medical technology company whose PlaqueIQ software performs FDA-cleared, histology-validated non-invasive analysis of coronary and carotid CT angiography to quantify atherosclerotic plaque for hospitals, imaging centers, and physician practices.
- Company typePrivate
- Founded2013
- HeadquartersBoston, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Elucid does
Elucid is a Boston-based AI medical technology company that develops PlaqueIQ, an FDA-cleared and CE-marked software platform that performs non-invasive analysis of coronary and carotid CT angiography (CTA) scans to quantify and classify atherosclerotic plaque. The core technology, branded CT Virtual Histology (CT-VH), uses proprietary algorithms trained and validated against tens of thousands of histopathologic tissue annotations from CVPath Institute, enabling differentiation of lipid-rich necrotic core (LRNC), calcified plaque, and non-calcified plaque with histology-level correlation (r=0.99 total plaque; r=0.88 LRNC). The product is delivered to physicians as a DICOM-wrapped PDF to PACS and an interactive browser interface, with a Lesion Inspection Tool enabling lesion-level analysis.
Elucid generates revenue by licensing PlaqueIQ to hospitals, imaging centers, and physician practices on a per-scan basis, with payment tied to reimbursement codes including CPT 75577 (effective January 2026 at a $1,012 national average) and Category III codes 0710T-0713T for LRNC quantification. Coverage now extends to over 70% of insured Americans through five of seven Medicare Administrative Contractors and major commercial payors (Aetna, Humana, Cigna, UnitedHealthcare). Go-to-market is enterprise field sales targeting hospitals, health systems, imaging centers, and clinical research institutions, supported by conference presence (SCCT, AHA, ACC), KOL engagement, and reimbursement support programs.
The company has raised approximately $157M cumulatively across multiple rounds including an $80M Series C led by Elevage Medical Technologies in November 2023, with an additional financing disclosed in October 2025. Operating geographies span the United States, United Kingdom, European Union, and South Korea. Plaque-Derived FFRCT, currently under development, is positioned to extend the platform into non-invasive fractional flow reserve measurement once FDA-cleared.
Elucid firmographics
Firmographics- Name
- Elucid
- Legal name
- Elucid Bioimaging Inc.
- Website
- http://elucid.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Elucid is a Boston-based AI medical technology company whose PlaqueIQ software performs FDA-cleared, histology-validated non-invasive analysis of coronary and carotid CT angiography to quantify atherosclerotic plaque for hospitals, imaging centers, and physician practices.
- Ownership category
- akta.pro rank
Elucid industry classification
Industry- Product category
- Cardiovascular Imaging Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
Keywords
Where Elucid is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Elucid business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- PlaqueIQ Software Licensing: Elucid generates revenue through licensing its PlaqueIQ software to hospitals, imaging centers, and physician practices. The software is used in conjunction with coronary CT angiography (CCTA) scans. Revenue is tied to reimbursement codes including Category I CPT code 75577 effective January 2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Coronary plaque analysis reimbursement for imaging centers and physician offices |
| Other | Pay-as-you-go | Hospital outpatient cardiac CT angiography |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Elucid product offering
Product offeringCore offering
Elucid develops and licenses PlaqueIQ, an FDA-cleared and CE-marked AI-powered image analysis software that performs non-invasive quantification and classification of atherosclerotic plaque morphology from coronary and carotid CT angiography scans, validated against ground-truth histology. The software delivers 3D vessel visualization, plaque component quantification (lipid-rich necrotic core, calcified, non-calcified), and lesion-level analysis tools to hospitals, imaging centers, and physician practices for cardiovascular disease risk assessment and treatment planning.
Product overview
Elucid is a Boston-based AI medical technology company offering a unified product ecosystem centered on Plaque-IQ, its flagship FDA-cleared and CE-marked AI-powered plaque analysis software. Plaque-IQ provides non-invasive CT angiography (CTA)-based plaque quantification and classification (including lipid-rich necrotic core) validated against ground-truth histology, available for both coronary and carotid arteries. A Lesion Inspection Tool within the Plaque-IQ suite adds lesion-level analysis capability. Elucid's investigational FFRCT product is derived from the Plaque-IQ algorithm, uniquely providing plaque concordance between plaque measurements and FFRCT values, pending FDA clearance. The company also offers clinical research services leveraging its CTA analysis platform. Plaque-IQ results are delivered as DICOM-wrapped PDFs to PACS and interactive browser-based reports.
Differentiator
Problem solved
Functional benefit
Brands
- PlaqueIQ: AI-powered image analysis software for quantification and classification of coronary and carotid plaque morphology, validated against ground truth histology. The only FDA-cleared non-invasive plaque analysis based on objective histology.
- Plaque-Derived FFRCT
- CT Virtual Histology (CT-VH)
Products and services
- PlaqueIQ Image Analysis Software FDA-cleared and CE-marked AI-powered image analysis software for non-invasive quantification and classification of atherosclerotic plaque morphology from CT angiography (CTA) scans. Validated against ground-truth histology, it classifies plaque into calcified, non-calcified, and lipid-rich necrotic core (LRNC) components, delivering 3D vessel visualization and actionable reports to PACS. Available for both coronary and carotid arteries.
- PlaqueIQ Image Analysis Software for the Carotid Arteries Carotid artery extension of the PlaqueIQ platform, the first and only CT-based plaque analysis software indicated for carotid anatomy. Enables physicians to quantify and classify plaque morphology in carotid arteries to assess risk of rupture and ischemic stroke, identifying lipid-rich necrotic core as a marker of cerebrovascular risk.
- Lesion Inspection Tool Lesion-level plaque composition analysis tool within the Plaque-IQ software suite that enables physicians to interrogate any specific lesion or region and access quantitative results for that segment, including lipid-rich necrotic core quantification at the individual lesion level.
- Elucid Clinical Research Services CTA analysis capabilities offered for clinical research applications including events tracking, pharmaceutical research, and investigator-initiated studies. Supports academic medical centers and research institutions conducting cardiovascular clinical research through a formal application process.
Quantifiable outcome
- Correlation with histology: Total Plaque r=0.99, Calcified r=0.95, Non-Calcified r=0.86, LRNC r=0.88
- +2 more outcomes
Companies that use Elucid
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Elucid technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Elucid partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Dr. Richard E. Kuntz, MD, MSccoreFormer senior VP and chief medical/scientific officer of Medtronic, founder and CSO of Harvard Clinical Research Institute, and interventional cardiologist at Brigham and Women's Hospital. Provides clinical trial strategy and product innovation guidance.
- Dr. Shamiram Feinglass, MD, MPHcoreManaging director at Manatt Health with expertise in market access, policy making, and regulatory strategy. Former executive at Danaher and Zimmer-Biomet, former regulator at CMS.
- CVPath InstitutecorePartnership with world-renowned cardiovascular pathologists at CVPath Institute for ground-truth histology validation. Dr. Renu Virmani serves as President & Medical Director and has validated Elucid's algorithms as highly accurate for tissue characterization compared to ex vivo histopathology.
- Emory University / Dr. Carlo De CeccocoreLead investigator for the PRE-VUE CCT Registry Study, an international multicenter trial evaluating PlaqueIQ's prognostic accuracy in predicting major cardiac adverse events.
- Gottsegen National Cardiovascular Center / Dr. Márton KolossvárycoreLead investigator for the PRE-VUE CCT Registry Study assessing PlaqueIQ and investigational FFRCT software in patients with clinically indicated CCTA.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Elucid competitors and assessment
Company assessmentDirect peers
- HeartFlow: Direct competitor in cardiac CT-based diagnostics. HeartFlow pioneered FFRCT (HeartFlow Analysis) for non-invasive assessment of coronary blockages and is the incumbent in CT-derived cardiac physiology assessment; Elucid's Plaque-Derived FFRCT directly targets this category with the addition of plaque concordance.
- Cleerly: Closest direct competitor in AI-powered CCTA plaque analysis. Cleerly offers software that quantifies and characterizes coronary plaque from CCTA scans, addressing the same cardiologist customer base with similar lesion-level plaque composition analysis.
- Circle Cardiovascular Imaging: Specialized cardiac imaging post-processing software vendor (cvi42) used by cardiologists and radiologists for CT and MR cardiac analysis. Comparable as a focused cardiac imaging software platform with similar customer workflows in advanced cardiac imaging.
Broad incumbents
- GE HealthCare: Major incumbent in cardiac CT imaging, scanners (Revolution CT), and AI-enabled post-processing (AI-Rad Companion). Comparable as the dominant OEM whose installed scanner base is the source of CCTA images that PlaqueIQ analyzes; overlapping capabilities in AI plaque characterization.
- Philips: Major incumbent in cardiac imaging (IQon Spectral CT, IntelliSpace Portal) and acquired Volcano Corporation (where Chairman Huennekens was previously CEO). Comparable as a broad imaging vendor with overlapping AI image analysis portfolio and direct cardiology channel.
- Siemens Healthineers: Major incumbent in cardiac CT (Force, NAEOTOM Alpha), post-processing software (syngo.via), and AI-augmented imaging. Comparable as the dominant OEM whose scanners produce CCTA images consumed by PlaqueIQ and which is building native AI plaque analytics.
- Canon Medical Systems: Major incumbent in cardiac CT scanners (Aquilion ONE) and Vitrea post-processing workstation with AI features. Comparable as a scanner OEM whose installed base produces CCTA images and which is embedding native plaque analysis capabilities.
Emerging players
- Arterys: Cloud-native AI medical imaging platform with FDA-cleared cardiac MRI and CT applications. Comparable as an AI imaging specialist addressing similar cardiology use cases with a SaaS delivery model.
- Aidoc: AI medical imaging company with broad radiology AI suite deployed in hospital workflows. Comparable as an enterprise imaging AI vendor competing for the same hospital IT budgets and clinical workflow integration slots.
- Viz.ai: AI medical imaging company focused on time-sensitive conditions (stroke, cardiology). Comparable as a specialty clinical AI workflow vendor with hospital enterprise sales motion and reimbursement-driven business model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Elucid social profiles
Digital presenceElucid compliance and trust
Trust signalCompliance3 records
Elucid financial estimates
Financial estimateRevenue estimate
Valuation estimate
Elucid leadership team
Management profileNumber of profiles
Profiles13 records
Elucid funding detail
Funding detailFunding overview
Funding rounds10 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Elucid M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Elucid
What does Elucid do?
Elucid develops and licenses PlaqueIQ, an FDA-cleared and CE-marked AI-powered image analysis software that performs non-invasive quantification and classification of atherosclerotic plaque morphology from coronary and carotid CT angiography scans, validated against ground-truth histology. The software delivers 3D vessel visualization, plaque component quantification (lipid-rich necrotic core, calcified, non-calcified), and lesion-level analysis tools to hospitals, imaging centers, and physician practices for cardiovascular disease risk assessment and treatment planning.
Is Elucid a public or private company?
Elucid is a private company. It is classified as venture growth investor backed and is currently operating.
When was Elucid founded?
Elucid was founded in 2013. It employs 101 to 250 people.
Where is Elucid based?
Elucid is headquartered in Boston, United States, in the North America region.
How does Elucid make money?
One revenue line is on record: plaqueIQ Software Licensing.
Who are Elucid's main competitors?
Direct peers on record are HeartFlow, Cleerly and Circle Cardiovascular Imaging. Broad incumbents are GE HealthCare, Philips, Siemens Healthineers and Canon Medical Systems. Emerging players are Arterys, Aidoc and Viz.ai.
Does Elucid have an API?
No public API is recorded for Elucid.
What industry is Elucid in?
Elucid's product category is Cardiovascular Imaging Software. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 334510 and its SIC code is 3841.